Find a Clinical Trial

Ipsen conducts first-in-the-world clinical trials to take science forward and bring innovative, new options to patients.

On this page you can find clinical trials that Ipsen has sponsored and clinical trials that were acquired by Ipsen. You can use the drop-down lists below to find clinical trials by condition, status, phase and country.

Completed clinical trials may also have results available. If so, a simple summary of the overall results can be found on the lay summaries page.

You may also find a scientific summary of the results on the US and EU Clinical Trial Registries.

The ‘status’ of participant recruitment is defined as follows:

  • Not yet recruiting – recruitment has not started yet
  • Recruiting – recruitment is open
  • Enrolling by invitation – recruitment is open to a particular population who are invited to participate.
  • Active, not recruiting – recruitment is closed, participants are still ongoing in the clinical trial;
  • Terminated – the study stopped early.
  • Completed – the study ended.






Showing : 15 of 152 clinical trials

Gastroenteropancreatic Neuroendocrine Tumors

satoreotide trizoxetan




68Ga-OPS202 Study for Diagnostic Imaging of GEP NET

The purpose of this study is to assess the safety and tolerability of 68Ga-OPS202 used for the diagnosis of gastroenteropancreatic neuroendocrine tumors (GEP NETs).

Healthy Participants


United Kingdom of Great Britain and Northern Ireland (the)United Kingdom of Great Britain and Northern Ireland (the)



A Comparative Study to Evaluate the Effects and Mechanism of Action of Dysport®, Botox® and Xeomin® in the Extensor Digitorum Brevis Model in Healthy Adult Male Participants

Study aimed at comparing the pharmacodynamic profile (including duration of action) of three commercialized toxins by measuring the action potential of the injected muscle (extensor digitorum brevis)

Neuroendocrine Tumors

satoreotide tetraxetan






United Kingdom of Great Britain and Northern Ireland (the)United Kingdom of Great Britain and Northern Ireland (the)


Active, Not Recruiting

Active, Not Recruiting

A Long-term Safety Surveillance Study in Participants Previously Treated With 177Lu-IPN01072

The purpose of the protocol is to evaluate the long-term safety of medicine 177Lu-satoreotide tetraxetan (also known as 177Lu-IPN01072 or 177Lu-OPS201) for patients who have previously received 177Lu-satoreotide tetraxetan in the clinical study OPS-C-001 / D-FR-01072-001.

Primary Biliary Cholangitis (PBC)


United States of America (the)United States of America (the)



A Long-Term Study of Elafibranor in Adult Participants with Primary Biliary Cholangitis

The participants of this study will have confirmed Primary Biliary Cholangitis (PBC). Participants will also have inadequate response or intolerance to ursodeoxycholic acid (UDCA). UDCA is a medication used in the management and treatment of PBC. PBC is a disease that progresses slowly. It causes damage to the bile ducts in the liver, leading to a build-up of bile acids which causes further damage. The liver damage in PBC may lead to scarring (cirrhosis). PBC may also be associated with multiple symptoms. Many people with PBC may require liver transplant or may die if the disease progresses and a liver transplant is not done. This study will compare a daily dose of elafibranor (the study drug) to a daily dose of placebo (a dummy treatment). Each participant will be in the study for about 7 years. The main aim of this study is to determine if elafibranor is better than placebo in preventing adverse (bad) clinical outcomes including progression of disease leading to liver transplant or death. This study will also study the safety of long-term treatment with elafibranor, as well as the impact on symptoms such as itching and tiredness.

Metastatic Castrate Resistant Prostate Cancer









United Kingdom of Great Britain and Northern Ireland (the)United Kingdom of Great Britain and Northern Ireland (the)






A Proof of Concept Study of Maintenance Therapy With Tasquinimod in Patients With Metastatic Castrate-resistant Prostate Cancer Who Are Not Progressing After a First Line Docetaxel Based Chemotherapy

The purpose of this study is to confirm that tasquinimod used as maintenance therapy is active and tolerable in patients with metastatic castrate-resistant prostate cancer not progressing after a first chemotherapy with docetaxel.